Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?

Vincenzo Graziano¹, Maria Teresa Scognamiglio², Marinella Zilli³, Jamara Giampietro³, Patrizia Vici⁴, Clara Natoli¹, and Antonino Grassadonia*¹,³

¹Department of Medical; Oral and Biotechnological Sciences; University “G. D’Annunzio”; Chieti, Italy; ²Medical Oncology Unit; “G. Bernabeo” Hospital; Ortona, Italy; ³Medical Oncology Unit; “SS. Annunziata” Hospital; Chieti, Italy; ⁴Division of Medical Oncology B; Regina Elena National Cancer Institute; Rome, Italy

Keywords: breast cancer, immune privilege, immune response, immune tolerance, pertuzumab, skin metastases, trastuzumab
Abbreviations: ADCC, Antibody-Dependent Cell-mediated Cytotoxicity; APCs, Antigen Presenting Cells; HER2, Human Epidermal Growth Factor Receptor 2; HR, hormonal receptors; IDC, invasive ductal carcinoma; T-regs, regulatory T cells; TLR, Toll-like receptor; TDM-1, Trastuzumab Emtansine

Introduction

Dual blockade of Human Epidermal Growth Factor Receptor 2 (HER2), obtained with the monoclonal antibodies Pertuzumab and Trastuzumab in combination with Taxanes is now consid- ered the best option for first line treatment of HER2-overexpressing metastatic breast cancer. Cleopatra trial has recently shown a significant increase in progression free survival and overall sur- vival when Pertuzumab is added to a standard treatment including Trastuzumab and Docetaxel.¹ This advantage has also been observed in patients who recurred after neoadjuvant/adjuvant Trastuzumab containing regimens, even if a definitive conclusion on this issue is limited by small sample size.²

However, the addition of Pertuzumab does not reduce the percentage of brain metastasis, a site usually considered a sanctuary where antibodies have limited efficacy.³ The reasons for this failure are generally attributed to the presence of the brain-blood barrier that strongly protects the nervous system from several drugs including monoclonal antibodies,⁴,⁵ or to the so called “immune privilege” of the brain,⁶,⁷ i.e. the lack of an adequate immune response in part required for monoclonal antibody effectiveness. This latter aspect is particularly important for Tras- tuzumab and Pertuzumab that, more than other antibodies, have been shown to function through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).⁸,⁹

Interestingly, immune privilege has been described also in the skin.¹⁰,¹¹ The exact mechanisms involved have been only partially elucidated, including (i) lack of MHC class II expression in Antigen Presenting Cells (APCs) determining impaired immune function in the inferior portions of hair follicles,¹⁰ (ii) production of potent immune-suppressants, such as TGF-β1 and α-melanocyte–stimulating hormone (α-MSH),¹⁰ or (iii) upregulation of the negative co-signaling molecule PD-L1 in der- mal papilla and dermal sheath cup cells.¹¹

Several cases of cutaneous progression after or during Trastuzumab regimens have been described in the literature, frequently associated with systemic disease progression.¹²,¹³

Herein we describe 2 cases in which patients with HER2-positive metastatic breast cancer had loco-regional cutaneous progres- sion during treatment with Pertuzumab and Trastuzumab despite an impressive systemic response.

We hypothesize that cancer cells located into the skin would survive and take proliferative advantage in virtue of an immune-tolerance mechanism that hampers trastuzumab-mediated ADCC.

Case presentation

Case 1

A 62-year-old woman came to our attention in October 2011 after she noticed a lump in her left breast. Clinical examination revealed a 7x5 cm mass with signs of inflammatory breast cancer. Bilateral breast MRI confirmed a mass-like lesion suggestive of
malignancy in the left breast. A tru-cut biopsy was performed and histopathology showed an invasive ductal carcinoma (IDC) with HER2-overexpressing phenotype: hormonal receptors (HR) negative, HER2 positive (3+), Ki67 30%.

A sequential scheme of Epirubicin plus Cyclophosphamide for 4 cycles followed by Docetaxel plus Trastuzumab for 4 cycles was administered as neoadjuvant therapy. A partial clinical response was obtained and total mastectomy with complete axillary node dissection was performed. Pathology revealed a residual cancer of 3 mm in the breast and the presence of metastases in 2 nodes. Immunohistochemistry confirmed the initial biology of the tumor. Staging was ypT1a, ypN1a, cM0.

She further underwent radiotherapy to the left chest wall and supraclavicular fossa, and received adjuvant Trastuzumab to complete 1 year. After 5 months, several red plaques appeared on her left chest skin, close to the surgical scar. Skin biopsy showed cutaneous infiltration of a highly proliferative (Ki67 70%) invasive ductal carcinoma of mammary origin. Neoplastic cells were negative for HR and strongly positive for HER2. Since there were no radiological signs of metastatic disease, a wide cutaneous excision was performed.

Unfortunately, 3 months later, red cutaneous plaques reappeared on her skin, in the site of previous excision, and a restaging CT scan showed secondary lesions in the liver (Fig. 1A-B). A first line chemotherapy with Pertuzumab, Trastuzumab and Docetaxel was started. A clinical objective response was achieved on the cutaneous lesions during the treatment and a CT scan performed after 5 cycles revealed a partial response in liver (Fig. 1C vs A and D vs B). Liver lesions gradually continued to reduce up to a complete radiological response after 12 cycles of treatment (Fig. 1E vs A and F vs B). At that time, paradoxically, red patches started to appear on her contralateral breast, similar to urticarial reaction. Patient’s right breast rapidly became oedematous and covered by little nodules resembling the plaques of the left chest wall that, in the meantime, increased in size and number, a clear sign of cutaneous cancer progression (Fig. 2).

A new CT scan confirmed that the patient was without any evidence of systemic progression and maintained a complete radiological response in the liver. She discontinued Pertuzumab plus Trastuzumab and started a new therapy with Trastuzumab Emtansine (TDM-1).

**Case 2**

A 50-year-old woman was admitted to our Breast Unit because of a typical appearance of inflammatory cancer in the left breast with small, well-circumscribed, solitary nodules in the trunk and in the base of the neck. Her left breast appeared swollen, red and oedematous. Bilateral mammography showed a 3 cm mass in the left breast with increased skin thickness. Mammogram was normal in the right breast. Biopsy confirmed the presence of lymphangitis carcinomatosis sustained by HER2-overexpressing, HR-negative IDC. Staging CT scan showed no sign of systemic disease and she started neoadjuvant therapy with Epirubicin plus Cyclophosphamide according to a dose-dense schedule (every 2 weeks).

**Figure 1.** Response in patient 1. CT scan shows liver metastasis presentation at basal time (A and B), after 5 cycles (C and D) and after 12 cycles (E and F) of chemotherapy containing Trastuzumab/Pertuzumab. The target lesions are indicated by arrows.

---

www.tandfonline.com  Cancer Biology & Therapy  1705
After four cycles she complained of pain in her right hip. Bone scan revealed the presence of multiple metastases in the spine and pelvis. MRI confirmed neoplastic lesions in all vertebra and pelvic bones (Fig. 3A). She underwent radiotherapy to the proximal part of her right femur and subsequently initiates first line therapy with Trastuzumab, Pertuzumab and Docetaxel. She rapidly reached clinical benefit: the inflammatory signs of the left breast gradually faded and the skin nodules decreased. Consistently, the MRI performed after 6 cycles demonstrated a dramatic reduction in number and size of bone metastases (Fig. 3B).

After 9 months of treatment (12 cycles) she noticed reddening of her trunk and a swollen, oedematous right breast, the contralateral one, resembling a cutaneous infection. Topical steroids, oral nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics were prescribed without any benefit. A biopsy of the para-areolar skin was performed and histological examination disclosed a HER2-overexpressing IDC. New small nodules appeared in the skin of the trunk and the pre-existing ones increased in size (Fig. 4). Nevertheless, disease remained in partial response in the bone and with no other site of metastatic spread as revealed by MRI (Fig. 3C) and CT scan, respectively. She discontinued treatment and started a second line therapy with TDM-1.

**Discussion**

To date, the contemporary use of 2 anti-HER2 antibodies, Pertuzumab and Trastuzumab, in association with Taxanes represents the best therapy for HER2-positive metastatic breast
cancer, and it is probably intended to become the best option in several lines of treatment. A remarkable median overall survival of almost 5 years has been reported for therapy-naïve metastatic patients.1,2

The two cases described herein are disappointing for the failure of Pertuzumab/Trastuzumab treatment because of diffuse cutaneous cancer progression in spite of an important systemic control of the disease. Skin metastases are rare events among all cancers, but develop in 24% of cases in advanced breast cancer,14 especially if HER2 overexpressing.15 Both our cases were inflammatory breast cancer, a biologically different type of neoplasm characterized by a high risk of local-regional recurrence, estimated around 20% even after a multimodal treatment including chemotherapy, surgery and radiotherapy, and at high risk of distant metastases.16 Once metastatic, the treatment of inflammatory cancer does not substantially differ from that of other types of breast cancers, even if the prognosis remain poor.

The appearance of reddening, oedematous area in the skin has been observed more frequently in patients treated with Pertuzumab plus Trastuzumab compared to Trastuzumab alone.1 In some cases the rush impose to investigate differential diagnosis between skin metastases and bacterial colonization sustained by Staphylococcus species.17 Biopsy is recommended in absence of clinical improvement after antibiotic and/or anti-inflammatory therapies. Our second patient had cutaneous manifestation resembling skin infection, but no clinical change was noticed after specific antibiotic treatment and the subsequent biopsy confirmed a malignant origin of the skin lesions.

In breast cancer patients cutaneous metastases are often associated with systemic progression of the disease,18 generally related to the selection of a more aggressive, resistant clone. Paradoxically, our 2 patients developed rapid progressive cutaneous metastases while achieving an impressive response in liver and bone, respectively.

Several mechanisms of resistance to Trastuzumab have been described in preclinical model,19 including epitope masking by mucin-4 (MUC4) or CD44 overexpression,20,21 expression of p95Her2, a truncated form of the HER2 protein,22 upregulation of HER2 downstream signaling pathways by loss of PTEN or PI3K mutations,23,24 and alteration of ADCC.25 Although the unique cancer progression in the skin might be due to the selection of a resistant clone according to the above mentioned mechanisms, we hypothesize a change in the tumor cutaneous microenvironment leading to the establishment of a sanctuary-like site in which tumor cells can easily escape from anti-HER2 directed antibodies. As a blood barrier that limits cutaneous distribution of antibodies has never been described, we hypothesize a process of acquired immune tolerance in the skin that impairs the ADCC triggered by Pertuzumab/Trastuzumab. This assumption comes from the following considerations.

First, impaired trastuzumab-mediated ADCC has been reported as a mechanism of resistance to Trastuzumab.19,25 Second, the selection of a resistant clone with an exclusive tropism for the skin, although possible, has never been described in breast cancer. Third, a huge systemic response with a parallel diffuse skin progression strongly suggest that the “soil,” i.e the skin, rather than the “seeds,” i.e., metastatic clones, is involved in this process. Fourth, the simultaneous progression in the skin of multiple pre-existing nodules, distant one from each other, is an evidence of an alteration in the drug/cancer cells/microenvironment interaction. It is hard to believe that a clonal selection takes place in different sites at the same time. Finally, the skin has been described as a site in which active mechanisms of immune tolerance can occur. Evidences have been provided showing that chronic infections26 or immunological tolerizing procedures27,28 can induce immune tolerance/privilege specific for skin tissue. The activation of regulatory T cells (T-reg) seems to be responsible for this immunosuppressive process.29,30

The idea that a local impaired immune system may promote skin metastases progression is supported by the evidence that topical imiquimod, a Toll-like receptor (TLR)-7 agonist, is active in the treatment of skin metastases from different neoplasms, including breast cancer,31-33 basal cell carcinoma34 and melanoma.35 TLRs are known to suppress the function of T-reg by breaking tolerance and enhancing immune responses against cancers.36-38

Understanding the mechanisms of induced immune privilege in the skin, including those occurring during Pertuzumab/Trastuzumab treatment, is essential for the development of new therapeutic strategies able to restore anti-tumor immune response. In
this way, an effective systemic therapy such as Pertuzumab/Trastuzumab could be continued while controlling skin metastases.

At our knowledge these are the first 2 cases of Pertuzumab-containing regimen discontinuation for progression of isolated cutaneous metastases despite a dramatic response in other metastatic sites, such as liver and bones. We hope future clinical trials could provide strategies to avoid giving up extremely efficient treatments, potentially curative for some patients, in a non-life-threatening condition like skin metastases.

Authors’ contributions
VG, MTS, MZ, JG and AG: treated the patients and collected the data; VG and AG reviewed the literature and wrote the paper; VG, AG, PV, CN, carried out critical interpretations. All authors read and approved the final manuscript.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
This work was supported from the Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO) and institutional funding from “G. D’Annunzio” University.

References
1. Baesij J, Corrêa J, Kim SB, Im SA, Hegg R, Im YH, Rosen J, Pedrini JL, Pietrzkowski T, Knott A, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366(2):109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa113216.
2. Swain SM, Baesij J, Kim SB, Ro J, Semiglazov V, Campone M, Circués E, Ferrero JM, Schneeweiss A, Heeson S, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372(8):724-34; PMID:25693012; http://dx.doi.org/10.1056/NEJMoa1415933.
3. Swain SM, Baesij J, Miles D, Im YH, Qahch C, Lee LF, Cortés J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol 2014; 25(6):1116-21; PMID:24685829; http://dx.doi.org/10.1093/annonc/mdu135.
4. Deksen JFL, Lischer W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007; 13(6):1663-74; PMID:17363519; http://dx.doi.org/10.1158/1078-0432.CCR-06-2854.
5. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Hirmawan HR, McFarlane JA, et al. Heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab, pertuzumab, and trastuzumab plus docetaxel therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 67(24):11991-9; PMID:17843477; http://dx.doi.org/10.1158/0008-5472.CAN-07-2068.
6. Niederkon IJ. See no evil, hear no evil, do no evil: the regulatory mechanism of immune privilege. J Invest Dermatol 2011; 131(5):1270-30; PMID:21458082; http://dx.doi.org/10.1170/jid.2013.14821.
7. De Giorgi V, Grazzini M, Alfaioli B, Savarese I, Corciova S, Guerriero G, Lotti T. Tumour microenvironment of breast carcinomas. Dermatol Ther 2010; 23(3):e127-30; PMID:24158082; http://dx.doi.org/10.1111/j.1529-8019.2010.01365.x.
8. Varchetta S, Gibelli N, Olibero R, Nardini E, Gennari S, Niederkorn JY. See no evil, hear no evil, do no evil: the regulatory mechanism of immune privilege. J Invest Dermatol 2011; 131(5):1270-30; PMID:21458082; http://dx.doi.org/10.1170/jid.2013.14821.
9. Scheur F, Fries T, Burrach H, Bossemeyer B, Endl J, Hauzenier M. Strongly enhanced in vivo tumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69(24):9360-3; PMID:19934333; http://dx.doi.org/10.1158/0008-5472.CAN-08-4597.
Waldmann H. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 2006; 213:239-55; PMID:16972908; http://dx.doi.org/10.1111/j.1600-065X.2006.00428.x

29. Daley SR, Ma J, Adams E, Cobbold SP, Waldmann H. A key role for TGF-β signaling to T cells in the long-term acceptance of allografts. J Immunol 2007; 179(6):3648-54; PMID:17785800; http://dx.doi.org/10.4049/jimmunol.179.6.3648

30. Yates SF, Paterson AM, Nolan KF, Cobbold SP, Saunders NJ, Waldmann H, Fairchild PJ. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol 2007; 179(2):967-76; PMID:17617588; http://dx.doi.org/10.4049/jimmunol.179.2.967

31. Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 2012; 18(24):6748-57; PMID:22767669; http://dx.doi.org/10.1158/1078-0432.CCR-12-1149

32. Mirer E, El Sayed F, Ammousry A, Lamant L, Messer L, Bazet J. Treatment of mammary and extramammary Paget’s skin disease with topical imiquimod. J Dermatol Treat 2006; 17(3):167-71; PMID:16854759; http://dx.doi.org/10.1080/09546630600788877

33. Henriques L, Palumbo M, Guay MP, Bahoric B, Baik M, Kavan P, Barst G. Imiquimod in the treatment of breast cancer skin metastasis. J Clin Oncol 2014; 32(8):e22-5; PMID:24419128; http://dx.doi.org/10.1200/JCO.2012.46.4883

34. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008; 13:859-75; PMID:18707162; http://dx.doi.org/10.1634/theoncologist.2008-0097

35. Hesling C, D’Incan M, Mansard S, Franck F, Corbin-Duval A, Chevetet C, Décélotte P, Madelmont JC, Veye A, Souteyrand P, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004; 150:761-7; PMID:15099376; http://dx.doi.org/10.1111/j.0007-0963.2004.05898.x

36. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double edged sword. Oncogene 2008; 27:218-24; PMID:18176603; http://dx.doi.org/10.1038/sj.onc.1210904

37. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008; 27:181-9; PMID:18176599; http://dx.doi.org/10.1038/sj.onc.1210906

38. Yusuf N. Toll-like receptor mediated regulation of breast cancer: a case of mixed blessings. Front Immunol 2014; 5:224; PMID:24904578; http://dx.doi.org/10.3389/fimmu.2014.00224

www.tandfonline.com Cancer Biology & Therapy 1709